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Abstract
Amniotic fluid stem (AFS) cells are broadly multipotent, can be expanded extensively in culture, are not tumorigenic and
can be readily cryopreserved for cell banking. Mesenchymal stem cells (MSC) show immunomodulatory activity and
secrete a wide spectrum of cytokines and chemokines that suppress inflammatory responses, block mixed lymphocyte
reactions (MLR) and other immune reactions, and have proven therapeutic against conditions such as graft-versus-host
disease. AFS cells resemble MSCs in many respects including surface marker expression and differentiation potential.
We therefore hypothesized that AFS cells may exhibit similar immunomodulatory capabilities. We present data to
demonstrate that direct contact with AFS cells inhibits lymphocyte activation. In addition, we show that cell-free
supernatants derived from AFS cells primed with total blood monocytes or IL-1b, a cytokine released by monocytes and
essential in mediation of the inflammatory response, also inhibited lymphocyte activation. Further investigation of AFS
cell-free supernatants by protein array revealed secretion of multiple factors in common with MSCs that are known to be
involved in immune regulation including growth related oncogene (GRO) and monocyte chemotactic protein (MCP) family
members as well as interleukin-6 (IL-6). AFS cells activated by PBMCs released several additional cytokines as compared to
BM-MSCs, including macrophage inflammatory protein-3a (MIP-3a), MIP-1a and Activin. AFS cells also released higher
levels of MCP-1 and lower levels of MCP-2 compared to BM-MSCs in response to IL-1b activation. This suggests that there
may be some AFS-specific mechanisms of inhibition of lymphocyte activation. Our results indicate that AFS cells are able
to suppress inflammatory responses in vitro and that soluble factors are an essential component in the communication
between lymphocytes and AFS cells. Their extensive self-renewal capacity, possibility for banking and absence of
tumorigenicity may make AFS cells a superior source of stable, well characterized ‘‘off the shelf’’ immunomodulatory cells
for a variety of immunotherapies.
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Introduction
Tissue engineering and cell therapy will be enhanced by
improved cell sources. Mesenchymal stromal cells (MSCs), an
adherent population found in nearly every adult tissue but most
often obtained from bone marrow (BM-MSCs) or adipose tissue,
have been examined for multiple clinical purposes [1,2,3,4,5].
MSCs can give rise to differentiated cells of the mesodermal
lineage including bone, fat, cartilage, tendon and muscle [6,7,8].
In addition, their ability to evade immunosurveillance after cell
transplantation and to suppress the immune response has made
BM-MSCs a particularly attractive candidate for clinical use
[9,10]. In particular, it was observed that BM-MSCs could
suppress lymphocyte proliferation and activation in response to
allogeneic activation or chemical stimulation in vitro or in vivo
[8,11,12].
Immunoregulation by BM-MSCs is thought to result from both
direct interactions between the stromal and immune cells
[13,14,15] and the actions of anti-inflammatory soluble factors
released by the stromal cells [2,16]. The secretion of these factors
occurs in response to pro-inflammatory signals from the local
environment, including IFN-c, TNF-a, IL-1a and IL-1b
[17,18,19]. Clinical applications for which the trophic action of
BM-MSCs may prove valuable include support of hematopoietic
transplantation and the treatment of graft versus host disease
(GvHD), osteogenesis imperfect, and acute myocardial infarction
[20,21,22,23,24]. However, the relatively limited proliferation of
BM-MSCs under standard conditions suitable for manufacture of
a clinical product presents a potential drawback for their medical
application [25]. For this reason, we sought to determine whether
amniotic fluid-derived stem (AFS) cells, which display considerably
greater expansion capacity and appear well suited to large-scale
banking [26] possess comparable immunomodulatory capability.
The amniotic fluid contains multiple cell types derived mainly
from exfoliating surfaces of the developing fetus [27]. These
include cells from the fetal skin, respiratory system, urinary and
gastrointestinal tracts, along with populations of MSCs [28]. De
Coppi et al. (2007) described a novel population of multipotent
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Kit (CD117), the cell surface receptor for stem cell factor (SCF),
and designated them amniotic fluid-derived stem (AFS) cells. AFS
cells are characterized by their high capacity for self-renewal and
their ability to differentiate to toward lineages representative of all
three germ layers including hepatocytes, osteocytes, chondrocytes
and adipocytes [26,29]. Some clonal AFS cell lines were shown to
proliferate in vitro well past Hayflick’s limit (greater than 80
population doublings) with no signs of malignant transformation,
chromosomal abnormalities, or loss of differentiation potential
[26]. AFS cells and BM-MSCs share many characteristics
including expression of the surface markers CD29, CD44,
CD73, CD90 and CD105. However, AFS cells also express the
more primitive stem cell marker SSEA4 [26]. The two cell types
also share a similar immune antigen surface profile with positive
MHC Class I expression but little to no MHC Class II expression.
MSCs also have the ability to avoid allogeneic rejection [30]. We
hypothesized that cells in the amniotic fluid may have immuno-
priviledged status, as fetal cells must possess mechanisms to avoid
destruction by the maternal immune system during development
[31]. We further hypothesized that, like MSCs, AFS cells also
possess immunosuppressive properties. There has been a single
report that unselected mesenchymal stromal cells from amniotic
fluid inhibit lymphocyte proliferation in vitro [32]. We sought to
determine whether cloned lines of CD117-selected AFS cells could
modulate immune responses.
Materials and Methods
AFS Cell and MSC Isolation and Culture
Human AFS cells were isolated as previously reported [26].
Briefly, back-up cultures from human amniocentesis were
obtained from the clinical cytogenetics laboratory and expanded
on petri dishes in a-MEM medium (Invitrogen, Carlsbad, CA)
containing 15% ES-FBS, 1% glutamine and 1% penicillin/
streptomycin (Invitrogen, Carlsbad, CA) and supplemented with
18% Chang B and 2% Chang C (Irvine Scientific, Irvine, CA).
Cultures were maintained at 37 C in a 5% CO2 atmosphere. Once
confluent, cells were immunoselected based on CD117 expression.
Cultures were trypsinized and single-cell suspensions labeled with
a rabbit polyclonal antibody against CD117 (Santa Cruz
Biotechnology, Santa Cruz, CA), then labeled with Goat Anti-
Rabbit IgG MicroBeads and selected on a Mini-MACS apparatus
(Miltenyi Biotech, Auburn, CA) following the protocol recom-
mended by the manufacturer. AFS cell lines A1 and H1 between
passages 15 and 20 were used for these experiments [26].
Human BM-MSCs were derived and cultured as previously
reported [33]. BM-MSC isolates were kindly provided by L.
Solchaga and cells between passages 3 and 5 were used for these
experiments.
Immunophenotype analysis of AFS cells and BM-MSCs
Human AFS cells and BM-MSCs at 70% confluence were
trypsinized and resuspended in PBS with 1% FBS. Cells were
incubated with FcR Block (Miltenyi Biotech, Auburn, CA) at room
temperature for 5 minutes, and then incubated with saturating
amounts of antibodies on ice for 30 minutes. The following FITC-
or PE- conjugated antibodies recognizing human antigens were
used: CD80, CD86, HLA-DR, HLA-ABC (BD Biosciences, San
Diego, CA). Each analysis included corresponding FITC- and/or
PE- conjugated isotype controls. Samples were run on a Becton
Dickinson FAC-Scan flow cytometric system (BD Biosciences, San
Diego, CA) and analysis was completed using FlowJo Software
(FlowJo, Ashland, OR).
Interferon-gamma ELISPOT analysis
(Phytohaemagglutinin (PHA) activation assay)
Elispot analysis was performed as described previously by
Maitra et al. (2006). Briefly, Multiscreen filter 96-well plates for
Elispot (Millipore, Billerica, MA) were coated with human
interferon-c (IFN-c) capture antibody (2G1; Endogen, Rockford,
IL). Peripheral blood mononuclear cells (PBMCs) were acquired
from AllCells (Emeryville, CA), activated with 5 mg/ml PHA
(L1668; Sigma, St. Louis, MO) and cultured in the IFN-c coated
wells with increasing stem cell densities or stem cell conditioned
medium. Experiments examining cell contact included wells with
150,000 PBMCs, 5 mg/ml PHA (L1668; Sigma, St. Louis, MO)
and increasing amounts of AFS cells or BM-MSCs (‘‘stem cells’’)
ranging from 4,688 (1:32 stem cell to PBMC ratio) to 75,000 stem
cells (1:2 stem cell to PBMC ratio). Controls included unstimulated
PBMCs and stimulated PBMCs with no stem cells. A minimum of
quadruplicate wells for each condition was analyzed in at least 3
independent experiments and a single representative experiment is
shown. After 24 hours, plates were washed and incubated with
biotinylated detection antibody (B133.5; Endogen, Rockford, IL)
for 2 hours at 37 C. Streptavidin-Horse Radish Peroxidase (HRP)
(P0397; Dako, Carpinteria, CA) was then added and incubated for
1 hour at room temperature. IFN-c spots were visualized after
incubation with 3-amino-9-ethylcarbazole (34004; Pierce, Rock-
ford, IL). An Elispot image analyzer was used to quantify the
number of spots in each well (Immunospot Cellular Technology,
Shaker Heights, OH). The percent activation for a given condition
was derived as the ratio of the mean spot number to the mean spot
number of the positive control, multiplied by 100.
Transwell experiments
Monolayers of AFS cells or BM-MSC were cultured in the
presence of total blood monocytes separated by trans-well chambers
(Corning, Corning, NY) or in the presence of IL-1b. In experiments
examining the effect of conditioned medium on the immune assay
each well included 150,000 PBMCs, 5 mg/ml PHA and 24 hour
conditioned medium from one of the following sources: 1) Basal
medium, 2) total blood moncytes, 3) AFS cells, 4) AFS cells cultured
with total blood monocytes, 5) AFS cells cultured with IL-1b,6 )
BM-MSCs, 7) BM-MSCs cultured with total blood monocytess, 8)
BM-MSCs cultured with IL-1b. Controls included unstimulated
PBMCs, which produced no IFN-c, and stimulated PBMCs in
growth medium, which produced the maximum amount of IFN-c.
A minimum of quadruplicate wells for each condition was analyzed
in at least 3 independent experiments and a single representative
experiment is shown. The Elispot plate was developed and analyzed
as described previously.
Cytokine secretion by antibody array
Cell-free supernatants from cells cultured under the eight
conditions outlined above were analyzed for cytokine secretion
using Cytokine Antibody Array V, VI, VII (RayBiotech, Norcross,
GA). Antibodies against each of 174 cytokines, chemokines and
growth factors were spotted onto the array membrane in
duplicate. After blocking for 30 minutes, the membranes were
incubated with 200 ml of supernatant at room temperature for
2 hours. Then primary biotin-conjugated antibody was added to
each well and incubated at room temperature for 2 hours.
Horseradish peroxidase-conjugated streptavidin was then added
to each well and incubated at room temperature for 30 minutes.
The wells were developed by addition of detection buffer and
analyzed using a luminescent image analyzer system (Gene-
Pix4000B, Axon Instruments, Union City, CA).
Amniotic Fluid Stem Cells Mediate Immune Response
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Semi-quantification of cytokine levels was achieved using Axon
software. The pixel density of each spot was measured and
background levels from negative controls were subtracted. The
intensity of positive control spots was used to normalize results
between the three membranes. The intensity for each cytokine was
then averaged over the duplicate spots. Controls of serum
containing medium, total blood monocytes cultured alone or stem
cells cultured alone wereincluded inthearray and these valueswere
subtracted as background from the appropriate samples.
Statistics
Results are expressed as mean +/2 standard deviation. The
statistical significance was determined by one way analysis of
variance (ANOVA). A p value,0.05 was considered statistically
significant.
Results
The purpose of these experiments is to compare stem cells
derived from amniotic fluid to mesenchymal stromal cells derived
from bone marrow in their ability to dampen the immune
response in vitro.
Immunogenic characterization of amniotic fluid stem
cells
We carried out flow cytometry to directly compare the
expression of immune-related surface markers between human
AFS cells and bone marrow-derived MSCs (BM-MSCs) (Figure 1).
Consistent with previous reports, the BM-MSCs were positive for
major histocompatibility complex (MHC) – Class I but expressed
no detectable MHCClass II (Figure 1A). The BM-MSCs also
showed no expression of the costimulatory molecules CD-80 and
CD86. AFS cells likewise demonstrated positive expression of
MHC – Class I and undetectable expression of MHC – Class II,
CD-80 and CD-86 (Figure 1B). To compare their response to
IFN-c, AFS cells and BM-MSCs were cultured in the presence of
the cytokine for 24 hours and flow cytometry was performed to
examine the expression of the same immune response related
surface markers. We found that IFN-c induced up-regulation of
MHC I and II, but not CD40, CD80, or CD86, in both BM-
MSCs (Figure 1A) and AFS cells (Figure 1B).
AFS cells suppress lymphocyte activation
The ability of AFS cells to inhibit lymphocyte activation by
PHA was examined in an Elispot assay measuring the pro-
inflammatory cytokine IFN-c. Two independent AFS cell lines, a
BM-MSC isolate and a human dermal fibroblast were tested in
this assay. Both AFS cell lines and the BM-MSC isolate induced
exerted dose-dependent inhibition of lymphocyte activation
(Figure 2). At low numbers of stem cells, the extent of inhibition
of lymphocyte activation by the AFS cells was essentially
equivalent to that for BM-MSCs. At a ratio of 1 stem cell, either
AFS or BM-MSC, to 32 lymphocytes, the percent activation was
about 70 percent of the positive control wells which contained no
stem cells. When the stem cell number was increased two-fold,
lymphocyte activation was further inhibited to 60 percent. By
increasing the number of stem cells again by two-fold we showed
decreased activation of lymphocytes to about 50 percent of the
positive control values. At the highest levels of stem cells, BM-
MSCs appeared slightly more potent than AFS cells, and
completely inhibited PHA-stimulated activation at the highest
dose tested. By contrast, control dermal fibroblasts did not inhibit
lymphocyte activation at any concentration.
Conditioned medium from AFS cells suppresses
lymphocyte activation
To examine the possibility that AFS cells secrete immunosup-
pressive factors, we assessed the effect of conditioned medium
(CM) in the lymphocyte activation assay. CM was prepared from
AFS cells and BM-MSCs with and without pre-treatment with the
pro-inflammatory cytokine IL-1b. CM also was prepared from
mixed cultures of AFS cells or BM-MSCs with PBMCs. CM from
unstimulated AFS cells or BM-MSC showed minimal suppression
(less than 10% reduction) of lymphocyte activation (Figure 3). CM
from AFS cells or BM-MSCs stimulated with IL-1b both showed
significantly enhanced suppression of PBMC activation, to 60–70
percent of control levels (Figure 3). CM obtained after stimulation
of AFS cells or BM-MSCs by co-culture with PBMCs also
significantly suppressed lymphocyte activation to a similar extent
compared to CM from IL-1b-stimulated cells.
Identification of secreted cytokines and growth factors
Medium conditioned by activated AFS cells and BM-MSCs
were examined by protein array to determine factors important in
immune response regulation. We assessed levels of 274 different
cytokines, chemokines and growth factors in CM from AFS cells
and BM-MSCs cultured under standard growth conditions or
activated with either PBMCs (Figure 4A) or IL-1b (Figure 4B).
Controls to assess background levels of soluble factors included
serum containing medium and PBMCs cultured alone. Two
identical arrays were completed on different days, one including
conditioned medium from 1) Cell free medium, 2) AFS cells, 3)
AFS cells activated with PBMCs and 4) AFS cells activated with
IL-1b and the other including 1) PBMC conditioned medium, 2)
BM-MSCs, 3) BM-MSCs activated with PBMCs, 4) BM-MSCs
activated with IL-1b.
Amniotic fluid stem cells and BM-MSCs under growth
conditions released low levels of very few cytokines. However,
upon activation by either PBMCs or IL-1b elevated levels of
cytokines were released and a similar cytokine profile was seen
from both AFS cells and BM-MSCs. Activation by PBMCs caused
release of high levels of several cytokines by AFS cells and BM-
MSCs including growth related cytokine – a (GRO-a), monocyte
chemotactic protein-3 (MCP-3) and interleukin – 6 (IL-6).
Granulocyte chemotactic protein -2 (GCP-2) and interleukin – 2
(IL-2) receptor alpha (IL-2Ra) were also released by both cell
types, although to a lesser extent. While PBMC activated AFS cells
released monocyte chemotactic protein-2 (MCP-2), macrophage
inflammatory protein 1a (MIP-1a), MIP-3a and Activin while
BM-MSCs did not.
Culture with pro-inflammatory cytokine IL-1b resulted in a
cytokine release profile similar to that seen with PBMC activation.
Both AFS cells and BM-MSCs released detectable levels of GRO,
GRO-a, MCP-1, IL-2, IL-6 and granulocyte macrophage colony
stimulating factor (GM-CSF). Each stem cell type also released low
levels of the cytokines MIP-3a, IL-2, regulated upon activation,
normal T-cell expressed, and secreted (RANTES) and epithelial
neutrophil-activating protein-78 (ENA-78). BM-MSCs released
detectable levels of several additional cytokines upon IL-1b
stimulation including GCP-2, Activin, IL-8 and insulin-like growth
factor-binding protein 4 (IGF-BP4).
Discussion
Human amniotic fluid stem (AFS) cells are broadly multipotent,
derived from an immunoprivileged site, can be expanded exten-
sively in culture, and do not form tumors when implanted in
immune deficient mice. We assessed AFS cells for immunomodulatory
Amniotic Fluid Stem Cells Mediate Immune Response
PLoS ONE | www.plosone.org 3 October 2011 | Volume 6 | Issue 10 | e26535Figure 1. The effect of IFN-c on the immunophenotype of AFS cells and BM-MSCs. BM-MSCs (A) or AFS cells (B) were cultured under
growth conditions with (blue) and without (yellow) addition of IFN-cstimulation for 24 hours. The cells were incubated with fluorescently labeled
antibodies against the the major histocompatibility complex molecules MHC-I and MHC-II as well as the costimulatory molecules CD40, CD80 and
CD86. The red line shows appropriate isotype controls. A. BM-MSCs under growth conditions express high levels of MHC-I and no MHC-II, CD40, CD80
or CD86. Upon IFN-c stimulation MSCs upregulate MHC-I and MHC-II while CD40, CD80 and CD86 remain unchanged. B. AFS cells show similar
expression patterns to MSCs with high levels of MHC-I and no MHC-II, CD40, CD80 or CD86. AFS cells also upregulate MHC-I and MHC-II in response
to IFN-c stimulation. Before stimulation they express high levels of MHC-I but low levels of MHC-II, CD40, CD80 and CD86. After IFN-c stimulation the
levels of MHC-I and MHC-II expression increase but CD80 and CD86 expression remains unchanged.
doi:10.1371/journal.pone.0026535.g001
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stromal cells (BM-MSCs). Characterization of AFS cell surface
markers revealed high expression of major histocompatibility
(MHC) Class I and lack of MHC Class II or co-stimulatory
molecules (CD80, CD86, CD40) consistent with previous reports
[8,16,26].Interferon-gamma(IFN-c) greatlyincreasedexpression of
both MHC Class I and MHCClass II.Thisindicatesthat AFS cells,
like MSCs, may not strongly activate rejection responses in
allogeneic hosts. We further observed that AFS cells, again like
MSCs, inhibit phytohemagglutinin (PHA)-induced activation of
lymphocytes in a dose-dependent manner. The mechanism of
immunosuppression by AFS cells involves both direct cell-cell
Figure 2. Human AFS cells inhibit lymphocyte activation in a dose dependent manner similar to that of BM-MSCs. Immunoassays
assessing lymphocyte activation were performed on two independent amniotic fluid stem cell lines (AFS1 and AFS2) or bone marrow-mesenchymal
stem cell (BM-MSC) isolates. T lymphocytes were activated with phytohemaaglutinin (PHA) and cultured in 96 well plates coated with IFN-c capture
antibody in the presence of increasing amounts of stem cells from 1:32 (4,688 stem cells cultured with 150,000 PBMCs) to 1:2 (75,000 stem cells
cultured with 150,000 PBMCs) for 24 hours. Positive control wells contained lymphocytes activated with PHA and negative control wells included
unactivated lymphocytes. Lymphocyte activation was assessed by counting the number of lymphocyte clones producing IFN-c. Activation is
expressed as a percentage of the positive control wells. Both AFS lines and BM-MSC inhibited T-cell compared to the PHA activated control to an
approximately equal extent, and was dependant on the number of stem cells added. Inhibition varied from about 40% at a 1:32 ratio to 80–90%
inhibition at the highest ratio of 1:2.
doi:10.1371/journal.pone.0026535.g002
Figure 3. AFS mediated immunosuppression does not require cell-cell contact. Amniotic fluid stem (AFS) cells from two independent
sources or bone marrow derived mesenchymal stem cells (BM-MSCs) were cultured under growth conditions (AFS 1, AFS 2, BM-MSC) or activated by
co-culture with total blood monocytes (AFS 1 PBMC, AFS 2 PBMC, BM-MSC PBMC) or IL-1b (AFS 1 IL1, AFS 2 IL1, BM-MSC IL1) to release soluble
factors. One way mixed lymphocyte reactions (MLR) were incubated in the presence of 24 hour conditioned medium from stem cells cultured with
either peripheral blood mononuclear cells (PBMCs) or IL-1b. PHA activated lymphocytes were cultured in 96 well plates coated with IFN-c capture
antibody in the presence of conditioned mediums for 24 hours. Positive control wells contained lymphocytes activated with PHA and negative
control wells contained unactivated lymphocytes. Lymphocyte activation was assessed by counting the number of clones producing IFN-c. Percent
activation was calculated by comparing wells containing stem cells to positive control wells. It can be seen that all supernatants were capable of
inhibiting T-cell activation by PHA by approximately 20–25%. All conditions are statistically significant when compared to the positive control wells.
doi:10.1371/journal.pone.0026535.g003
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interaction through immunosuppressive factors secreted by the stem
cells in response to activation. Analysis of cell-free supernatants
demonstrated a substantial overlap in the cytokine release profiles of
AFS cells and BM-MSCs, either at rest or when activated with
PBMCs or interleukin 1-beta (IL-1b). In response to activation, the
most highly upregulated protein in both cell types was interleukin 6
(IL-6). IL-6 is a broad-acting cytokine involved in the control of the
immune response as well as stem cell development and regulation
[20,34]. Mesenchymal stem cells derived from cord blood (CB-
MSCs) and BM-MSCs have also been reported to secrete high
amounts of IL-6 when activated with IL-1b [35]. The biological
relevance of this IL-6 response likely lies in both local and systemic
protection against inflammation [36,37]. BM-MSCs and AFS cells
also released high levels of growth related oncogene family members
GRO and GRO-a as well as monocyte chemotactic protein-1 (MCP-
1) upon IL-1b activation. These chemokines have well known effects
on cellsof the immune system and are important in inflammation and
wound healing. GRO acts on neutrophils and MCP-1 acts mainly on
macrophages, recruiting them to sites of inflammation [38].
Compared to BM-MSCs, activated AFS cells released signifi-
cantly higher levels of several cytokines including MCP-2, MIP-3a
and MIP-1a whereas the activated BM-MSCs released signifi-
cantly higher levels of GRO-a, MCP-3, GCP-2 and IL-8. These
data suggest that AFS cells may possess some alternative molecular
mechanisms to modulate the immune response. In this regard, we
have recently compared the effect of rat AFS (rAFS) and rat BM-
MSC (rBM-MSC) in a rat model of experimental necrotising
enterocolitis (NEC). We were able to show that rAFS cells
significantly improved the survival and enhanced the repair of the
damaged intestine, whereas rBM-MSC had no effect (Paolo De
Coppi, personal communication). Similar results have been
achieved using human AFS cells to repair the kidney and restore
its function in an immunodeficient mouse model of acute tubular
necrosis (ATN) [39]. In this model AFS cells appear to possess
immunomodulatory function, initiating the release of several
murine anti-inflammatory cytokines and reducing the release of
pro-inflammatory cytokines [39].
Current stem cell therapies using MSCs require large cell doses
and as a result of the limited growth potential of MSCs, cells from
Figure 4. Soluble factors released from AFS cells and BM-MSCs in response to activation. Amniotic fluid stem (AFS) cells or bone marrow
derived mesenchymal stem cells (BM-MSCs) were activated by culture with A. total blood monocytes or B. IL-1b and the cytokines released were
measured by cytokine array. Background cytokine levels were subtracted to normalize samples and include cytokines released by PBMCs cultured
alone and stem cells cultured alone. Quantification of protein optical density was measured using GenePix4000 software.
doi:10.1371/journal.pone.0026535.g004
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which results in variation between treatments. AFS cells have the
unique advantage of extensive self-renewal in vitro allowing for
long-term expansion, full characterization and cryopreservation.
These factors make AFS cells an ideal source for cell banking and
standardized ‘off the shelf’ therapeutic use, allowing them to serve
as a reproducible immunomodulatory cell therapy source especially
for autoimmune-type diseases.
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